What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice […]

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026 Read Post »

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026

We are thrilled to release five brand-new “Patients Empowering Patients” talks — five women, three countries (Italy, Turkey, the US), and five very different stories, all united by the same resilience and positive outlook that defines this community. From Aygün Mengelli Tomur’s lung transplant journey “From Waiting to Breathing: A New Beginning,” to Deger Kesimogluğlu’s

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026 Read Post »

US Food and Drug Administration (FDA) updates Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension

The US Food and Drug Administration (FDA) has approved an update to the US label for WINREVAIR (sotatercept-csrk), Merck’s activin signaling inhibitor for pulmonary arterial hypertension, to include efficacy and safety data from the Phase 3 HYPERION trial. The trial specifically evaluated adults newly diagnosed with pulmonary arterial hypertension — within 12 months of screening,

US Food and Drug Administration (FDA) updates Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension Read Post »

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care!

The Alliance for Pulmonary Hypertension (AfPH) is back with the third instalment of their 2026 webinar series exploring how new science and AI are transforming pulmonary arterial hypertension care. This session taking place on September 28 at 6 pm CEST brings together leading experts from the US, UK, and Netherlands to explore where the field

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care! Read Post »

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026

A prospective, randomised, controlled single-centre study looking at whether fluid restriction (FR) helps pulmonary arterial hypertension patients with right heart failure and signs of volume overload. 41 patients (average age 70, mostly World Health Organisation (WHO) Functional class III, were split between intensified fluid restriction counselling (around 1.5 litres per day) and routine fluid restriction

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026 Read Post »

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026

The French Pulmonary Hypertension Association HTaPFrance is holding its 6th Patient Congress, 13–15 November 2026 at Centre Valpré in Écully, France — coinciding with the association’s 30th anniversary. The congress is open to pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH patients, those awaiting or having received a transplant, along with their families,

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026 Read Post »

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026

The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) were presented today at the ERS Congress! The Alliance for Pulmonary Hypertension Vice President Louise Bouman – van der Waal was at the congress and attended this important session. Here is the link to the article: https://lnkd.in/evX7wHhe Pisana Ferrari, President of

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026 Read Post »

On 19th September, pulmonary hypertension nurses Iain Armstrong and Javier Jimenez are taking the plunge for patients for “Swim Serpentine”, covering 1,609 metres, in London’s Hyde Park

On 19th September, pulmonary hypertension nurses Iain Armstrong (Chairman of the UK pulmonary Hypertension association), and Javier Jimenez will spend one mile experiencing what their patients face every single day. They will swim in the open water of London’s Hyde Park for Swim Serpentine, covering 1,609 metres in the heart of the city. The shock

On 19th September, pulmonary hypertension nurses Iain Armstrong and Javier Jimenez are taking the plunge for patients for “Swim Serpentine”, covering 1,609 metres, in London’s Hyde Park Read Post »

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026

Some patients with pulmonary arterial hypertension experience difficulties with memory, thinking, or mood. A group of Chinese researchers have investigated whether reduced blood flow to the brain is connected to heart strain and disease severity. They compared brain scans from 30 people with pulmonary arterial hypertension and 51 healthy individuals matched for age and sex.

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026 Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026

The findings of a multi-center randomized controlled trial investigating the long-term efficiency of rehabilitation in patients with pulmonary arterial hypertension was published in the Annals of the American Thoracic Society on July 20, 2026. The study followed 47 patients with stable pulmonary arterial hypertension across 9 French centers, looking at the long-term impact of a

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 Read Post »

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026

In a recent LinkedIn post Prof. Werner Seeger writes that the GoDeep meta-registry analysis about the predictive power of pulmonary artery stiffness – right ventricular interplay in mild pulmonary hypertension (PH) is now online. He reports that in the analysis, notably, parameters integrating pulsatile vascular load and interdependent right ventricular function possess predictive power independent

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 Read Post »

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026

The US Food and Drug Administration (FDA) has accepted for review a New Drug Application from United Therapeutics Corporation for ralinepag, an investigational prostacyclin IP receptor agonist intended to treat pulmonary arterial hypertension (PAH). The filing rests on results from the Phase III ADVANCE OUTCOMES study See our previous article on this topic here. Read more at

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available

A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill patients in the Intensive Care

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available Read Post »

Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society

Krishma Kaur and his cousin Sean Bhaker, UK citizens, have decided to take on the challenge of climbing Mount Kilimanjaro to raise money for Alzheimer’s Society and the UK Pulmonary Hypertension Association PHA UK. All money raised will be donated directly to these two charities. Krishma and Sean have launched a Go Fund campaign to

Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society Read Post »

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition

A narrative review on inhaled pulmonary vasodilators (iPVs) in perioperative pulmonary hypertension (PH) management was published recently in Key points: Background: Pulmonary hypertension significantly raises perioperative morbidity/mortality risk, especially in cardiac and high-risk non-cardiac surgery. Traditional IV vasodilators (nitroglycerin, sodium nitroprusside) lack pulmonary selectivity and cause systemic hypotension. Established agents: The review compares five main

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition Read Post »

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026

For 30 years, pulmonary arterial hypertension (World Health Organisation, WHO, Group 1 pulmonary hypertension) treatment relied on three vasodilator-based pathways: endothelin receptor antagonists (bosentan, ambrisentan, macitentan), the nitric oxide/cGMP pathway (sildenafil, tadalafil, riociguat), and prostacyclin pathway agents (treprostinil, epoprostenol, selexipag, etc.). These improve symptoms and slow progression but don’t modify the underlying vascular disease, and

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026 Read Post »

From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide

he pathway to medical breakthroughs is often laden with surprises, errors, and serendipity, reads and article in a magazine called Mirage. The article dates back to 2023 but we found it still relevant and interesting as it mentions two iaccidental discoveries, warfaring and sildenail citrate that are have transformed the care of pulmonary arterial hypertension

From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide Read Post »

TRANSLATE »
Scroll to Top